Asunercept
Based on 1 Customer Validation
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.13%
- No. CAS: 1450882-18-4
- Peso molecular:84.05 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
In Vitro
Asunercept (APG101; 0-100 µg/mL; preincubation for 30 min) specifically neutralizes the proapoptotic activity of recombinant CD95L in Jurkat A3 cells[1].
Asunercept (0.2, 2, 20 µg/mL; 72 h) is capable of interfering with CD95-induced migration/invasion of glioma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat A3 cells (APG293-induced)
-
Concentration:0-100 µg/mL
-
Incubation Time:30 min (preincubation)
-
Result:Completely neutralized APG293-induced apoptosis.
-
Cell Line:U87-MG cells (CD95L knockdown; APG293-induced)
-
Concentration:0.2, 2, 20 µg/mL
-
Incubation Time:72 h
-
Result:Blocked APG293 induced invasion of U87 cells (CD95L knockdown).
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
[FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR)superfamily member 6, FAS1, APO-1, CD95)]2-IGHG1 Fc (Fragment constant)
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Asunercept can bind Anti-Fas/CD95/TNFRSF6 Antibody. The EC50 for this effect is 38.57 ng/mL.
Chemical Information
-
No. CAS 1450882-18-4
-
Appearance Liquid
-
Peso molecular 84.05 kDa
-
Color Colorless to light yellow
-
SMILES
[Asunercept]
-
Synonyms
APG101; CAN008
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26(7):716-27. [Content Brief]
[2]. Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100. [Content Brief]
[3]. Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel). 2020 Dec 8;12(12):3683. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Asunercept Related Classifications
HY-P99445 Related Classifications
Powered by Bioz